These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6882625)

  • 1. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
    Nauta IL; van de Calseyde JF
    Curr Med Res Opin; 1981; 7(4):215-26. PubMed ID: 7226872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of intravenous disopyramide in 126 cases of cardiac rhythm disorders (author's transl)].
    Ducloux G; Faivre G; Perrin A; Raynaud R; Canicave JC; Fauchier JP; Groussin P; Loire R; Saulnier JP
    Ann Cardiol Angeiol (Paris); 1978; 27(4):297-302. PubMed ID: 80150
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of multiple bolus loading of intravenous disopyramide.
    Simpson RJ; Foster JR; Benge C; Baker S; Gettes LS
    Am Heart J; 1983 Sep; 106(3):505-8. PubMed ID: 6881023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiarrhythmic action of disopyramide: a study of plasma levels].
    Page A; Pic A; Besse P
    Arch Mal Coeur Vaiss; 1979 Jul; 72(7):774-80. PubMed ID: 117775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiarrhythmic effect of intravenous disopyramide in an open study.
    Tonkin AM; Heddle WF; Bett JH; Kemp RJ; Donnelly GL; Nelson GI; Manolas E; Sloman JG
    Aust N Z J Med; 1982 Aug; 12(4):271-5. PubMed ID: 6958238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical pharmacology of disopyramide].
    Rewerski W; Dorociak A; Walczak F; Dobiasz A
    Pol Tyg Lek; 1980 Jul; 35(29):1109-12. PubMed ID: 7001399
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.